Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Glicksman

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 27, 2021
Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT AnalysisR M Glicksman, A U Kishan, A J Katz, et al.
European Urology Open Science|May 31, 2022
Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell TumorsPeter J Gariscsak, Lynn Anson-Cartwright, Eshetu G Atenafu, et al.
Urologic Oncology|June 20, 2020
Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practiceNoelia Sanmamed, Rachel M Glicksman, Jaime Herrera-Caceres, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 29, 2021
Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trialRachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
International Journal of Radiation Oncology, Biology, Physics|November 18, 2023
Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT)Rachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
Clinical and Translational Radiation Oncology|September 25, 2024
Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trialsRachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 6, 2021
Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trialsRachel M Glicksman, Stanley K Liu, Patrick Cheung, et al.
International Journal of Radiation Oncology, Biology, Physics|January 8, 2025
Clinical Outcomes of Stage IIA/IIB Seminoma Treated With Radiation Therapy and Chemotherapy: Should Regional Therapy be Considered the Preferred Treatment Approach?Rachel M Glicksman, Di Maria Jiang, Philippe L Bedard, et al.
Neurology|February 20, 1999
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathyD B Clifford, C Yiannoutsos, M Glicksman, et al.
International Journal of Radiation Oncology, Biology, Physics|September 13, 2024
The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled TrialRachel M Glicksman, Srinivas Raman, Xiang Y Ye, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 27, 2021
Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT AnalysisR M Glicksman, A U Kishan, A J Katz, et al.
European Urology Open Science|May 31, 2022
Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell TumorsPeter J Gariscsak, Lynn Anson-Cartwright, Eshetu G Atenafu, et al.
Urologic Oncology|June 20, 2020
Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practiceNoelia Sanmamed, Rachel M Glicksman, Jaime Herrera-Caceres, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 29, 2021
Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trialRachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
International Journal of Radiation Oncology, Biology, Physics|November 18, 2023
Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT)Rachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
Clinical and Translational Radiation Oncology|September 25, 2024
Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trialsRachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 6, 2021
Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trialsRachel M Glicksman, Stanley K Liu, Patrick Cheung, et al.
International Journal of Radiation Oncology, Biology, Physics|January 8, 2025
Clinical Outcomes of Stage IIA/IIB Seminoma Treated With Radiation Therapy and Chemotherapy: Should Regional Therapy be Considered the Preferred Treatment Approach?Rachel M Glicksman, Di Maria Jiang, Philippe L Bedard, et al.
Neurology|February 20, 1999
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathyD B Clifford, C Yiannoutsos, M Glicksman, et al.
International Journal of Radiation Oncology, Biology, Physics|September 13, 2024
The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled TrialRachel M Glicksman, Srinivas Raman, Xiang Y Ye, et al.
Pageof 6